The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.
 
Filippo Gustavo Dall'Olio
No Relationships to Disclose
 
Damien Vasseur
No Relationships to Disclose
 
Maryam Karimi
No Relationships to Disclose
 
Stefan Michiels
Consulting or Advisory Role - Biophytis; IQvia; Kedrion Biopharma; Roche; Sensorion; SERVIER; Yuhan
 
Ludovic Lacroix
No Relationships to Disclose
 
Pascale Tomasini
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb Foundation; Janssen; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Pfizer; Takeda
 
Judith Raimbourg
No Relationships to Disclose
 
Noemie pata-Merci
No Relationships to Disclose
 
Catherine Daniel
No Relationships to Disclose
 
Henri Janicot
No Relationships to Disclose
 
Anne Madroszyk
Consulting or Advisory Role - AstraZeneca; Roche
 
Clarisse Audigier-Valette
Consulting or Advisory Role - Abbvie; AstraZeneca; BMSi; Lilly O.; MSD; Roche
 
Ivan Bieche
No Relationships to Disclose
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Pierre Fabre; Roche
 
Denis Lucien MORO SIBILOT
Honoraria - Abbvie; Becton Dickinson; Lilly O.; Novartis; Pfizer; Roche; Takeda; Viatris
 
Marta Jimenez
No Relationships to Disclose
 
Jean-Charles Soria
Employment - Amgen
Stock and Other Ownership Interests - Amgen; Gritstone Bio; Relay Therapeutics
 
Virginie Westeel
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Ipsen
Speakers' Bureau - Amgen; Bristol-Myers Squibb/Pfizer; Lilly; MSD
Travel, Accommodations, Expenses - AstraZeneca; Bristol Myers Squibb; Roche; Sanofi
 
Fabrice Barlesi
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai Europe (Inst); Lilly (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Genzyme (Inst); Genzyme (Inst); Hedera Dx (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); socar (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst)